Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INSULET CORPPODD · Entity 3516 | Director | May 20, 2026 | May 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INSULET CORP
Report date May 20, 2026 · Filed May 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,438 |
Reported balance
After 2026-05-20 transaction · row 1
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 1,660 · Balance 2,438 F1: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs, which will be settled in shares of common stock on a one-for-one basis, vest in full on April 30, 2027. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 17,483 |
Reported balance
Holding disclosure · report date 2026-05-20 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 17,483 |
Filing footnotes · ownership attribution and instrument terms
F1: Annual equity award in the form of restricted stock units ("RSUs"). These RSUs, which will be settled in shares of common stock on a one-for-one basis, vest in full on April 30, 2027.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ABIOMED INC
Report date December 22, 2022 · Filed December 27, 2022
Section 16 reporting ended · disclosed 2022-12-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock $.01 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-12-22 transaction · row 1
1 source rowRow 1 · 2022-12-22 · Disposition to issuer · Disposed 166,670 · Balance 0 F1: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. F2: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share. F3: This number reflects unvested Company RSU Awards and shares of common stock. The Form 4 filed on December 20, 2022 for Michael Minogue inadvertently omitted unvested Company RSU Awards from the balance of non-derivative securities beneficially owned by the reporting person. |
| Common Stock $.01 par valueSEC Table I · non-derivative | IndirectBy Trust | 0 |
Reported balance
After 2022-12-22 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2022-12-22 · Disposition to issuer · Disposed 243,962 · Balance 0 F1: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement. F3: This number reflects unvested Company RSU Awards and shares of common stock. The Form 4 filed on December 20, 2022 for Michael Minogue inadvertently omitted unvested Company RSU Awards from the balance of non-derivative securities beneficially owned by the reporting person. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.55 · Expires 2024-05-14 | Direct | 0 |
Reported balance
After 2022-12-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-12-22 · Disposition to issuer · Disposed 85,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $66.25 · Expires 2025-05-13 | Direct | 0 |
Reported balance
After 2022-12-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-12-22 · Disposition to issuer · Disposed 35,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.62 · Expires 2026-05-24 | Direct | 0 |
Reported balance
After 2022-12-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-12-22 · Disposition to issuer · Disposed 30,500 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $134.51 · Expires 2027-05-15 | Direct | 0 |
Reported balance
After 2022-12-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-12-22 · Disposition to issuer · Disposed 33,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $381.97 · Expires 2028-05-16 | Direct | 0 |
Reported balance
After 2022-12-22 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-12-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $266.39 · Expires 2029-05-30 | Direct | 0 |
Reported balance
After 2022-12-22 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-12-22 · Disposition to issuer · Disposed 50,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $223.90 · Expires 2030-05-29 | Direct | 0 |
Reported balance
After 2022-12-22 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-12-22 · Disposition to issuer · Disposed 20,898 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $283.88 · Expires 2031-05-25 | Direct | 0 |
Reported balance
After 2022-12-22 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-12-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option; F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option. |
| Performance Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 96,265 |
Reported balance
After 2022-12-22 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-12-22 · Grant · Acquired 96,265 · Balance 96,265 F6: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) F7: and (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)). |
| Performance Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2022-12-22 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2022-12-22 · Disposition to issuer · Disposed 96,265 · Balance 0 F6: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance) F7: and (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)). |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed in connection with transactions contemplated by the Agreement and Plan of Merger, dated as of October 31, 2022 (the "Merger Agreement"), by and among the Issuer, Johnson & Johnson ("Parent") and Athos Merger Sub, Inc. ("Merger Sub"), pursuant to which, on December 22, 2022, Merger Sub was merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent. As a result of the Merger, each outstanding share of common stock, par value $0.01 per share, of the Issuer (each, an "Issuer Share") was automatically converted into the right to receive (i) an amount in cash equal to $380.00 (the "Cash Amount"), plus (ii) one non-tradeable contingent value right (the "CVR"), representing the right to receive contingent payments of up to $35.00 per Issuer Share, payable upon the achievement of certain specified milestones set out in the Contingent Value Rights Agreement.
F2: Pursuant to the Merger Agreement, each award of restricted stock units of the Issuer, excluding any award of restricted stock units with vesting subject to performance-based conditions ("Company RSU Award"), outstanding as of immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company RSU Award and (B) the Cash Amount and (ii) one CVR per Issuer Share.
F3: This number reflects unvested Company RSU Awards and shares of common stock. The Form 4 filed on December 20, 2022 for Michael Minogue inadvertently omitted unvested Company RSU Awards from the balance of non-derivative securities beneficially owned by the reporting person.
F4: Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each option to purchase Issuer Shares that was outstanding and unexercised immediately prior to the Effective Time was canceled and converted into the right to receive: (1) with respect to each stock option with a per share exercise price less than the Cash Amount (an "In-the-Money Option"), (A) an amount in cash, without interest, equal to the product of (I) the aggregate number of Issuer Shares underlying such In-the-Money Option and (II) the excess, if any, of (x) the Cash Amount over (y) the per share exercise price of such In-the-Money Option and (B) one CVR per Issuer Share underlying such In-the-Money Option;
F5: ; and (2) with respect to each stock option with a per share exercise price that was greater than or equal to the Cash Amount (an "Out-of-the-Money option"), upon each Valuation Point (as defined in the Merger Agreement) occurring after the Effective Time, an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Out-of-the-Money Option and (B) (I) the excess, if any, of (x) the Per Share Value Paid (as defined in the Merger Agreement) as of such Valuation Point over (y) the per share exercise price of such Out-of-the-Money Option, less (II) the amount of all payments previously received with respect to such Out-of-the-Money Option.
F6: Pursuant to the Merger Agreement, each award of restricted stock units with vesting subject to performance-based conditions ("Company PSU Award") outstanding immediately prior to the Effective Time was canceled and converted into the right to receive (i) an amount in cash, without interest, equal to the product of (A) the aggregate number of Issuer Shares underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of December 22, 2022 (the "Closing Date") and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as of the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)
F7: and (B) the Cash Amount, and (ii) one CVR for each Issuer Share underlying such Company PSU Award (assuming (1) the actual level of performance for performance metrics for which the relevant performance period has been completed as of the Closing Date and (2) the maximum level of performance under the terms of the applicable award agreement as in effect on the date of the Merger Agreement for performance metrics for which the relevant performance period has not been completed as the Closing Date (subject, in the case of Company PSU Awards granted to the Chief Executive Officer of the Company, to a maximum level of performance of 200% of the target level of performance)).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 16, 2018 Filed May 18, 2018 21:49 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 2,185 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-018178 · form4.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,358 F1 · shares: The 2,185 restricted stock units vest on April 30, 2019, subject to continued service as a director or consultant. Vested shares will be delivered to the reporting person as soon as practicable following a vesting date. F2 · balance_after: Includes 3,173 restricted stock units granted on August 10, 2017, which vest one-half of the restricted stock units on August 10, 2018, one-quarter of the restricted stock units on August 10, 2019 and one-quarter of the restricted stock units on August 10, 2020, subject to continued service as a director or consultant. Read SEC document |
| May 15, 2018 Filed May 16, 2018 17:44 UTC | ABIOMED INC ABMD · Entity 121309 | Tax withholdingCommon Stock $.01 par value | 10,568 | $375.67 | $3,970,080.56 |
DisclosureSEC source: 0001179110-18-006912 · edgar.xml · nonDerivative · entry 3 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,154 F5 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F5 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document |
| May 15, 2018 Filed May 16, 2018 17:44 UTC | ABIOMED INC ABMD · Entity 121309 | GrantCommon Stock $.01 par value | 57,340 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-006912 · edgar.xml · nonDerivative · entry 2 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,722 F6 · kind: Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on May 15, 2017. One third of these restricted stock units vested on May 15, 2018 (into an equal number of shares of common stock) based on the issuer's achievement of a certain performance milestone and upon the first anniversary of the date of the grant with the remaining vesting on the second and third anniversaries of the date of grant as long as the reporting person continues to be employed by the issuer on the vesting dates. F6 · shares: Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on May 15, 2017. One third of these restricted stock units vested on May 15, 2018 (into an equal number of shares of common stock) based on the issuer's achievement of a certain performance milestone and upon the first anniversary of the date of the grant with the remaining vesting on the second and third anniversaries of the date of grant as long as the reporting person continues to be employed by the issuer on the vesting dates. Read SEC document |
| May 13, 2018 Filed May 16, 2018 17:44 UTC | ABIOMED INC ABMD · Entity 121309 | Tax withholdingCommon Stock $.01 par value | 11,237 | $372.68 | $4,187,805.16 |
DisclosureSEC source: 0001179110-18-006912 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,382 F5 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. F5 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with the vesting of awards of restricted stock units in accordance with the time periods set forth in such awards. Read SEC document |
| March 31, 2018 Filed Apr 3, 2018 16:02 UTC | ABIOMED INC ABMD · Entity 121309 | GrantCommon Stock $.01 par value | 85 | $290.99 | $24,734.15 |
DisclosureSEC source: 0001179110-18-005196 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,018 F5 · kind: These shares of common stock were acquired by the reporting person through participation in the ABIOMED, Inc. Employee Stock Purchase Plan, qualified under Section 423 of the Internal Revenue Code, and the transaction was exempt under Rule 16b-3(c). F5 · shares: These shares of common stock were acquired by the reporting person through participation in the ABIOMED, Inc. Employee Stock Purchase Plan, qualified under Section 423 of the Internal Revenue Code, and the transaction was exempt under Rule 16b-3(c). Read SEC document |
| November 30, 2017 Filed Apr 3, 2018 16:02 UTC | ABIOMED INC ABMD · Entity 121309 | GiftCommon Stock $.01 par value | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-005196 · edgar.xml · nonDerivative · entry 5 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust - B Disclosed balance after: 38,000 F7 · kind: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. F8 · kind: This transaction represents the transfer of common stock by bona fide gift from a trust held for the benefit of reporting person's spouse to a trust held for the benefit of reporting person's children. F7 · shares: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. F8 · shares: This transaction represents the transfer of common stock by bona fide gift from a trust held for the benefit of reporting person's spouse to a trust held for the benefit of reporting person's children. Read SEC document |
| November 30, 2017 Filed Apr 3, 2018 16:02 UTC | ABIOMED INC ABMD · Entity 121309 | GiftCommon Stock $.01 par value | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-005196 · edgar.xml · nonDerivative · entry 4 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust - A Disclosed balance after: 119,779 F7 · kind: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. F8 · kind: This transaction represents the transfer of common stock by bona fide gift from a trust held for the benefit of reporting person's spouse to a trust held for the benefit of reporting person's children. F7 · shares: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. F8 · shares: This transaction represents the transfer of common stock by bona fide gift from a trust held for the benefit of reporting person's spouse to a trust held for the benefit of reporting person's children. Read SEC document |
| November 29, 2017 Filed Apr 3, 2018 16:02 UTC | ABIOMED INC ABMD · Entity 121309 | GiftCommon Stock $.01 par value | 10,399 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-005196 · edgar.xml · nonDerivative · entry 3 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust - A Disclosed balance after: 134,779 F6 · kind: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse in a trustee of the trust. F7 · kind: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. F6 · shares: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse in a trustee of the trust. F7 · shares: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 29, 2017 Filed Apr 3, 2018 16:02 UTC | ABIOMED INC ABMD · Entity 121309 | GiftCommon Stock $.01 par value | 10,399 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-005196 · edgar.xml · nonDerivative · entry 2 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,619 F6 · kind: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse in a trustee of the trust. F7 · kind: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. F6 · shares: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse in a trustee of the trust. F7 · shares: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 30, 2017 Filed Oct 4, 2017 16:06 UTC | ABIOMED INC ABMD · Entity 121309 | GrantCommon Stock $.01 par value | 61 | $168.60 | $10,284.60 |
DisclosureSEC source: 0001179110-17-013087 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,002 F5 · kind: These shares of common stock were acquired by the reporting person through participation in the ABIOMED, Inc. Employee Stock Purchase Plan, qualified under Section 423 of the Internal Revenue Code, and the transaction was exempt under Rule 16b-3(c). F5 · shares: These shares of common stock were acquired by the reporting person through participation in the ABIOMED, Inc. Employee Stock Purchase Plan, qualified under Section 423 of the Internal Revenue Code, and the transaction was exempt under Rule 16b-3(c). Read SEC document |
| August 10, 2017 Filed Aug 11, 2017 20:38 UTC | INSULET CORP PODD · Entity 3516 | GrantStock Option (Right to Buy) · Derivative | 4,226 | $0.00 Strike: $52.53 | $0.00 |
DisclosureSEC source: 0001127602-17-025503 · form4.xml · derivative · entry 2 MINOGUE MICHAEL R · CIK 0001286370 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,226 Underlying: Common Stock · 4,226 shares Expires 2027-08-10 F2 · derivative.exercise_date: This option is subject to a three-year vesting period with 50% of the total award vesting on the first anniversary of the date of grant and 25% of the total award vesting on each of the second and third anniversaries of the date of grant, subject to continued service as a director or consultant. Read SEC document |
| August 10, 2017 Filed Aug 11, 2017 20:38 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 3,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-025503 · form4.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,173 F1 · balance_after: The 3,173 restricted stock units vest 50% of the total award on the first anniversary of the date of grant and 25% of the total award on each of the second and third anniversaries of the date of grant, subject to continued service as a director or consultant. Read SEC document |
| May 30, 2017 Filed Oct 4, 2017 16:06 UTC | ABIOMED INC ABMD · Entity 121309 | GiftCommon Stock $.01 par value | 37,069 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-013087 · edgar.xml · nonDerivative · entry 3 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust - A Disclosed balance after: 124,380 F6 · kind: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse in a trustee of the trust. F7 · kind: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. F6 · shares: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse in a trustee of the trust. F7 · shares: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 30, 2017 Filed Oct 4, 2017 16:06 UTC | ABIOMED INC ABMD · Entity 121309 | GiftCommon Stock $.01 par value | 37,069 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-013087 · edgar.xml · nonDerivative · entry 2 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,933 F6 · kind: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse in a trustee of the trust. F7 · kind: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. F6 · shares: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse in a trustee of the trust. F7 · shares: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| May 24, 2017 Filed May 26, 2017 16:06 UTC | ABIOMED INC ABMD · Entity 121309 | Tax withholdingCommon Stock $.01 par value | 7,612 | $134.74 | $1,025,640.88 |
DisclosureSEC source: 0001179110-17-008069 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,941 F5 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with vesting of awards of restricted stock units. F5 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with vesting of awards of restricted stock units. Read SEC document |
| May 15, 2017 Filed May 17, 2017 16:53 UTC | ABIOMED INC ABMD · Entity 121309 | GrantStock Option (right to buy) · Derivative | 33,000 | $0.00 Strike: $134.51 | $0.00 |
DisclosureSEC source: 0001179110-17-007425 · edgar.xml · derivative · entry 17 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2027-05-15 F4 · security: Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2015 Omnibus Incentive Plan. F3 · derivative.exercise_date: These options become exercisable in annual 33-1/3% increments, commencing on the date shown in Table II, Column 6. Read SEC document |
| May 15, 2017 Filed May 17, 2017 16:53 UTC | ABIOMED INC ABMD · Entity 121309 | GrantCommon Stock $.01 par value | 13,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-007425 · edgar.xml · nonDerivative · entry 3 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,076 F11 · kind: Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of May 15, 2018, May 15, 2019 and May 15, 2020, so long as the reporting person continues to be employed by the issuer on the vesting dates. F11 · shares: Consists of restricted stock units granted to the reporting person. One third of the restricted stock units will vest and the underlying shares will be issued to the reporting person on each of May 15, 2018, May 15, 2019 and May 15, 2020, so long as the reporting person continues to be employed by the issuer on the vesting dates. Read SEC document |
| May 15, 2017 Filed May 17, 2017 16:53 UTC | ABIOMED INC ABMD · Entity 121309 | GrantCommon Stock $.01 par value | 37,483 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-007425 · edgar.xml · nonDerivative · entry 2 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,176 F10 · kind: Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on May 24, 2016. One third of these restricted stock units will vest on May 24, 2017 (into an equal number of shares of common stock) based on the issuer's achievement of a certain performance milestone and upon the first anniversary of the date of the grant with the remaining vesting on the second and third anniversaries of the date of grant as long as the reporting person continues to be employed by the issuer on the vesting dates. F10 · shares: Represents shares of common stock underlying performance-based awards of restricted stock units granted to this reporting person on May 24, 2016. One third of these restricted stock units will vest on May 24, 2017 (into an equal number of shares of common stock) based on the issuer's achievement of a certain performance milestone and upon the first anniversary of the date of the grant with the remaining vesting on the second and third anniversaries of the date of grant as long as the reporting person continues to be employed by the issuer on the vesting dates. Read SEC document |
| May 15, 2017 Filed May 17, 2017 16:53 UTC | ABIOMED INC ABMD · Entity 121309 | Tax withholdingCommon Stock $.01 par value | 25,396 | $131.42 | $3,337,542.32 |
DisclosureSEC source: 0001179110-17-007425 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,693 F5 · kind: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with vesting of awards of restricted stock units. F5 · shares: Transaction represents shares of common stock withheld solely for the payment of withholding tax liability associated with vesting of awards of restricted stock units. Read SEC document |
| March 31, 2017 Filed Apr 4, 2017 18:57 UTC | ABIOMED INC ABMD · Entity 121309 | GrantCommon Stock $.01 par value | 117 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-005696 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,089 F5 · kind: These shares of common stock were acquired by the reporting person through participation in the ABIOMED, Inc. Employee Stock Purchase Plan, qualified under Section 423 of the Internal Revenue Code, and the transaction was exempt under Rule 16b-3(c). F5 · shares: These shares of common stock were acquired by the reporting person through participation in the ABIOMED, Inc. Employee Stock Purchase Plan, qualified under Section 423 of the Internal Revenue Code, and the transaction was exempt under Rule 16b-3(c). Read SEC document |
| November 21, 2016 Filed May 17, 2017 16:53 UTC | ABIOMED INC ABMD · Entity 121309 | GiftCommon Stock $.01 par value | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-007425 · edgar.xml · nonDerivative · entry 9 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust - C Disclosed balance after: 9,000 F8 · kind: This transaction represents the transfer of common stock by bona fide gift from a trust held for the benefit of reporting person's spouse to a charitable foundation. F9 · kind: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. F8 · shares: This transaction represents the transfer of common stock by bona fide gift from a trust held for the benefit of reporting person's spouse to a charitable foundation. F9 · shares: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 21, 2016 Filed May 17, 2017 16:53 UTC | ABIOMED INC ABMD · Entity 121309 | GiftCommon Stock $.01 par value | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-007425 · edgar.xml · nonDerivative · entry 8 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust - A Disclosed balance after: 87,311 F8 · kind: This transaction represents the transfer of common stock by bona fide gift from a trust held for the benefit of reporting person's spouse to a charitable foundation. F9 · kind: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. F8 · shares: This transaction represents the transfer of common stock by bona fide gift from a trust held for the benefit of reporting person's spouse to a charitable foundation. F9 · shares: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 10, 2016 Filed May 17, 2017 16:53 UTC | ABIOMED INC ABMD · Entity 121309 | GiftCommon Stock $.01 par value | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-007425 · edgar.xml · nonDerivative · entry 7 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust - B Disclosed balance after: 23,000 F7 · kind: This transaction represents the transfer of common stock by bona fide gift from a trust held for the benefit of reporting person's spouse to a trust held for the benefit of reporting person's children. F9 · kind: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. F7 · shares: This transaction represents the transfer of common stock by bona fide gift from a trust held for the benefit of reporting person's spouse to a trust held for the benefit of reporting person's children. F9 · shares: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 10, 2016 Filed May 17, 2017 16:53 UTC | ABIOMED INC ABMD · Entity 121309 | GiftCommon Stock $.01 par value | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-007425 · edgar.xml · nonDerivative · entry 6 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust - A Disclosed balance after: 96,311 F7 · kind: This transaction represents the transfer of common stock by bona fide gift from a trust held for the benefit of reporting person's spouse to a trust held for the benefit of reporting person's children. F9 · kind: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. F7 · shares: This transaction represents the transfer of common stock by bona fide gift from a trust held for the benefit of reporting person's spouse to a trust held for the benefit of reporting person's children. F9 · shares: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 10, 2016 Filed May 17, 2017 16:53 UTC | ABIOMED INC ABMD · Entity 121309 | GiftCommon Stock $.01 par value | 26,523 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-007425 · edgar.xml · nonDerivative · entry 5 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust - A Disclosed balance after: 119,311 F6 · kind: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse in a trustee of the trust. F9 · kind: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. F6 · shares: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse in a trustee of the trust. F9 · shares: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 10, 2016 Filed May 17, 2017 16:53 UTC | ABIOMED INC ABMD · Entity 121309 | GiftCommon Stock $.01 par value | 26,523 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-007425 · edgar.xml · nonDerivative · entry 4 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,553 F6 · kind: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse in a trustee of the trust. F9 · kind: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. F6 · shares: This transaction represents the transfer of common stock by bona fide gift from the reporting person to a trust held for the benefit of the reporting person's spouse. The reporting person's spouse in a trustee of the trust. F9 · shares: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 16:11 UTC | ABIOMED INC ABMD · Entity 121309 | GrantCommon Stock $.01 par value | 73 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-030253 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,972 F5 · kind: These shares of common stock were acquired by the reporting person through participation in the ABIOMED, Inc. Employee Stock Purchase Plan, qualified under Section 423 of the Internal Revenue Code, and the transaction was exempt under Rule 16b-3(c). F5 · shares: These shares of common stock were acquired by the reporting person through participation in the ABIOMED, Inc. Employee Stock Purchase Plan, qualified under Section 423 of the Internal Revenue Code, and the transaction was exempt under Rule 16b-3(c). Read SEC document |
| September 27, 2016 Filed Sep 29, 2016 16:09 UTC | ABIOMED INC ABMD · Entity 121309 | Tax withholdingCommon Stock $.01 par value | 23,550 | $126.72 | $2,984,256.00 |
DisclosureSEC source: 0001179110-16-030084 · edgar.xml · nonDerivative · entry 2 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,899 F6 · kind: Transaction represents shares of common stock withheld solely for payment of withholding tax liability associated with the vesting of awards of restricted stock units. F6 · shares: Transaction represents shares of common stock withheld solely for payment of withholding tax liability associated with the vesting of awards of restricted stock units. Read SEC document |
| September 27, 2016 Filed Sep 29, 2016 16:09 UTC | ABIOMED INC ABMD · Entity 121309 | GrantCommon Stock $.01 par value | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-030084 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,449 F5 · kind: These performance-based awards of restricted stock units were granted to this reporting person on June 27, 2011. These restricted stock units vested on September 27, 2016 upon the issuer's achievement of a certain regulatory milestone. F5 · shares: These performance-based awards of restricted stock units were granted to this reporting person on June 27, 2011. These restricted stock units vested on September 27, 2016 upon the issuer's achievement of a certain regulatory milestone. F5 · price: These performance-based awards of restricted stock units were granted to this reporting person on June 27, 2011. These restricted stock units vested on September 27, 2016 upon the issuer's achievement of a certain regulatory milestone. Read SEC document |
| September 22, 2016 Filed Sep 23, 2016 17:24 UTC | ABIOMED INC ABMD · Entity 121309 | Exercise / conversionStock Option (right to buy) · Derivative | 28,039 | $0.00 Strike: $5.86 | $0.00 |
DisclosureSEC source: 0001179110-16-030006 · edgar.xml · derivative · entry 5 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires 2019-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan. F5 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F5 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F1 · derivative.exercise_date: These options become exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6. Read SEC document |
| September 22, 2016 Filed Sep 23, 2016 17:24 UTC | ABIOMED INC ABMD · Entity 121309 | SaleCommon Stock $.01 par value | 28,039 | $127.07 | $3,562,823.20 |
DisclosureSEC source: 0001179110-16-030006 · edgar.xml · nonDerivative · entry 2 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,449 F5 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F5 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F6 · price: This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $127.0000 and $127.8600. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 22, 2016 Filed Sep 23, 2016 17:24 UTC | ABIOMED INC ABMD · Entity 121309 | Exercise / conversionCommon Stock $.01 par value | 28,039 | $5.86 | $164,308.54 |
DisclosureSEC source: 0001179110-16-030006 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F5 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. Read SEC document |
| September 21, 2016 Filed Sep 21, 2016 16:57 UTC | ABIOMED INC ABMD · Entity 121309 | SaleCommon Stock $.01 par value | 5,034 | $127.07 | $639,690.01 |
DisclosureSEC source: 0001179110-16-029895 · edgar.xml · nonDerivative · entry 6 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,449 F7 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F7 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F8 · price: This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $127.0000 and $127.1700. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer. Read SEC document |
| September 21, 2016 Filed Sep 21, 2016 16:57 UTC | ABIOMED INC ABMD · Entity 121309 | Exercise / conversionCommon Stock $.01 par value | 5,034 | $5.86 | $29,499.24 |
DisclosureSEC source: 0001179110-16-029895 · edgar.xml · nonDerivative · entry 5 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,483 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F7 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. Read SEC document |
| September 19, 2016 Filed Sep 21, 2016 16:57 UTC | ABIOMED INC ABMD · Entity 121309 | Exercise / conversionStock Option (right to buy) · Derivative | 28,661 | $0.00 Strike: $5.86 | $0.00 |
DisclosureSEC source: 0001179110-16-029895 · edgar.xml · derivative · entry 11 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,039 Underlying: Common Stock · 0 shares Expires 2019-05-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan. F7 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F7 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F2 · derivative.exercise_date: These options become exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6. Read SEC document |
| September 19, 2016 Filed Sep 21, 2016 16:57 UTC | ABIOMED INC ABMD · Entity 121309 | Exercise / conversionStock Option (right to buy) · Derivative | 6,750 | $0.00 Strike: $18.63 | $0.00 |
DisclosureSEC source: 0001179110-16-029895 · edgar.xml · derivative · entry 10 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires 2018-08-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan. F7 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F7 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F4 · derivative.exercise_date: These options become exercisable based on the achievement of certain performance milestones. Read SEC document |
| September 19, 2016 Filed Sep 21, 2016 16:57 UTC | ABIOMED INC ABMD · Entity 121309 | Exercise / conversionStock Option (right to buy) · Derivative | 28,333 | $0.00 Strike: $13.80 | $0.00 |
DisclosureSEC source: 0001179110-16-029895 · edgar.xml · derivative · entry 9 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 0 shares Expires 2018-05-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Grant to reporting person of option to buy shares of Common Stock under the ABIOMED, Inc. 2000 Stock Incentive Plan. F7 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F7 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F2 · derivative.exercise_date: These options become exercisable in annual 25% increments, commencing on the date shown in Table II, Column 6. Read SEC document |
| September 19, 2016 Filed Sep 21, 2016 16:57 UTC | ABIOMED INC ABMD · Entity 121309 | SaleCommon Stock $.01 par value | 58,710 | $127.00 | $7,456,170.00 |
DisclosureSEC source: 0001179110-16-029895 · edgar.xml · nonDerivative · entry 4 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,449 F7 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F7 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. Read SEC document |
| September 19, 2016 Filed Sep 21, 2016 16:57 UTC | ABIOMED INC ABMD · Entity 121309 | Exercise / conversionCommon Stock $.01 par value | 23,627 | $5.86 | $138,454.22 |
DisclosureSEC source: 0001179110-16-029895 · edgar.xml · nonDerivative · entry 3 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,159 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F7 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. Read SEC document |
| September 19, 2016 Filed Sep 21, 2016 16:57 UTC | ABIOMED INC ABMD · Entity 121309 | Exercise / conversionCommon Stock $.01 par value | 6,750 | $18.63 | $125,752.50 |
DisclosureSEC source: 0001179110-16-029895 · edgar.xml · nonDerivative · entry 2 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F7 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. Read SEC document |
| September 19, 2016 Filed Sep 21, 2016 16:57 UTC | ABIOMED INC ABMD · Entity 121309 | Exercise / conversionCommon Stock $.01 par value | 28,333 | $13.80 | $390,995.40 |
DisclosureSEC source: 0001179110-16-029895 · edgar.xml · nonDerivative · entry 1 MINOGUE MICHAEL R · CIK 0001286370 · Director · President, CEO, Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · kind: Sale of common stock pursuant to reporting owner's 10b5-1 plan. F7 · shares: Sale of common stock pursuant to reporting owner's 10b5-1 plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.